哌拉西林/他唑巴坦与头孢哌酮/舒巴坦治疗儿童中重度细菌性肺炎的疗效观察

Clinical effect of piperacillin/tazobactam and cefoperazone/sulbactam for children with moderate-to-severe bacterial pneumonia

目的评价哌拉西林/他唑巴坦及头孢哌酮/舒巴坦治疗儿童中重度细菌性肺炎的临床疗效及安全性。方法随机选择60例中重度细菌性肺炎患儿分成两组,每组各30例,一组使用哌拉西林/他唑巴坦治疗,另一组使用头孢哌酮/舒巴坦治疗,观察患儿的临床疗效及药物不良反应发生率。结果 30例哌拉西林/他唑巴坦治疗组中,治愈22例,显效5例,总有效率为90.0%,2例有不良反应发生,发生率为6.7%;主要表现为皮疹及腹泻各1例;30例细菌培养阳性10例,阳性率为33.3%,细菌清除9例,清除率为90%;30例头孢哌酮/舒巴坦治疗组中治愈20例,显效5例,总有效率为83.3%,1例有不良反应发生,发生率为3.3%;主要表现为皮疹;30例细菌培养中,阳性10例,阳性率为33.3%,细菌清除8例,清除率为80.0%;两组临床疗效及清除率比较,差异均无统计学意义,所有入选病例均完成治疗,未因药物不良反应而中止治疗。结论哌拉西林/他唑巴坦和头孢哌酮/舒巴坦治疗儿童中重度细菌性肺炎的临床疗效肯定,安全性良好。

OBJECTIVE To evaluate the clinical effects and safety of piperacillin/tazobactam and cefoperazone/sulbactam to children with moderate-to-severe-bacterial pneumonia.METHODS A total of 60 children with moderate to severe bacterial pneumonia were randomly divided into 2 groups with 30 cases in each,one group was treated with piperacillin/tazobactam,while the other was treated with cefoperazone/sulbactam.The clinical efficacy and the incidence of adverse reactions in the children were observed.RESULTS In group treated with piperacillin/tazobactam,22 cases were cured,efficacy markedly worked in 5 cases and the total effective rate was 90.0%,adverse reaction occurred in 2 cases with the incidence of 6.7%;there was 1 case of skin rashes and 1 case of diarrhea;10 of 30 cases（33.3%） were cultured positive with the positive rate of 33.3%,bacteria were eradicated in 9 cases with the eradication rate of 90%;while in group treated with cefoperazone/sulbactam,20 cases were cured,5 cases efficacy markedly worked in 5 cases,the total effective rate was 83.3%,adverse reaction occurred in 1 case with the incidence of 3.3%,mainly presenting as skin rashes;10 of 30 cases were cultured positive with the positive rate of 33.3%,the bacteria were eradicated in 8 cases with the eradication rate of 80.0%;the differences in clinical effect and bacterial eradication rate between the two groups were not statistically significant.the treatment for all of the study cases was completed without any stop caused by adverse reaction.CONCLUSION The clinical effect of piperacillin/tazobactam and cefoperazone/sulbactam for children with moderate-to-severe-bacterial pneumonia is definite,and the safety is remarkable.